Download Free Compendium Of Assays For Immunodiagnosis Of Human Cancer Book in PDF and EPUB Free Download. You can read online Compendium Of Assays For Immunodiagnosis Of Human Cancer and write the review.

This book presents the timeline of immunodiagnostics evolution, including advancements in immunological/nucleic acid probes, assay design, labelling techniques, and devices for signal transduction and acquisition. In the past few years, enzyme and nanocatalyst-based immune assays have undergone numerous modifications to enhance their sensitivity and potential for automation. Further, to reduce production costs and the use of laboratory animals, engineering small antibodies and nucleic acid probes (aptamers) has become increasingly popular in the development of novel and powerful bioassays. In light of the notable advancements in immunodiagnostics, this book highlights the combined efforts of clinicians, biotechnologists, material scientists, nanotechnologists and basic scientists in a coherent and highly structured way. The book takes readers on the journey of immunodiagnostic technologies, from their introduction to the present.
The ability to diagnose cancer by simple measurement of a serum or tissue' 'marker" has been a goal of medical science for many years. There is ample evidence that tumor cells are different from normal cells and pro duce substances that can be detected by currently available immuno chemical or biochemical methods. These "cancer markers" may be se creted proteins, enzymes, hormones, fetal serum components, monoclonal immunoglobulins, cell surface components, or cytoplasmic constituents. The purpose of this book is to present the current status of our knowledge of such cancer markers. The first tumor marker identified by laboratory means was Bence Jones protein. In a series of lectures delivered to the Royal College of Phy sicians in London in 1846, Dr. H. Bence Jones described studies on a urine sample sent to him with the following note: "Dear Dr. Jones-The tube contains urine of very high specific gravity. When boiled it becomes slightly opaque . . . . etc. " Dr. Jones found that heating of the urine after addition of nitric acid resulted in formation of a heavy precipitate; acid ad dition may have been required to bring the urine to pH 4-6 at which Bence Jones proteins are more likely to precipitate when heated. This urinary pre cipitate was associated with a bone disease termed "mollities ossium. " [H. Bence Jones, Papers on Chemical Pathology, Lecture III. Lancet 2, 269-274 (1847)].
Updated to reflect changes in the field since publication of the first edition in 1979. Provides a detailed review of the methodology available for assessing the diagnosis and prognosis of cancer patients including data on the application of tumor marker assays and other immunodiagnostic procedures
Developmental cancer products (oncodevelopmental markers, ODM) not only serve as diagnostic and prognostic indicators but also may be used to study the nature of the carcinogenic process and the biology of tumors. For many years oncologists have searched for markers of cancer cells that would permit unequivocal recognition of cancer in contrast to noncancerous tissue. The earliest and still most widely used method of identification of cancer tissue or cells is the structural resemblance of cancer tissue to fetal or immature tissue. Pathologists not only recognize cancer by its morphologic similarity to fetal tissues, but also in many instances can relate the behavior of a given tumor to the degree of tissue differentiation. Thus, poorly differentiated tumors that resemble fetal tissue generally grow more rapidly and metastasize earlier than do well-differentiated tumors that more closely resemble adult tissue. In recent years the commonality of fetal and cancer tissue has been extended to products of tumor cells that, can be analyzed by biochemical, immunological, or physiological techniques. Increas ingly, products of cancer cells similar to fetal products are being identified and studied. These products range from cell-surface markers (fetal or differentiation antigens), placental proteins, hormones, and isoenzymes to a multitude of products, such as carcinoembryonic antigen (CEA), alphafetoprotein (AFP), lymphocyte markers, and nucleic acids, such as tRNA, that are produced in small amounts by v vi PREFACE continually differentiating cells in the adult but in much greater amounts by tumors.
First multi-year cumulation covers six years: 1965-70.